Home/Pipeline/OMN-002

OMN-002

Glycogen storage disease type II

PreclinicalActive

Key Facts

Indication

Glycogen storage disease type II

Phase

Preclinical

Status

Active

Company

Omnes Therapeutics

About Omnes Therapeutics

A Belgian AAV‑based gene‑therapy platform targeting rare metabolic diseases.

View full company profile

Therapeutic Areas